EMA Safety Commission Recommends Withdrawal Of Esmya Authorizations
Follows March Suspension By EMA
Marketing authorizations for Gedeon Richter’s Esmya and generic versions are certain to be revoked, after a review by the EMA’s safety committee concluded that the uterine fibroids drug “can cause liver injury, including the need for liver transplantation.”
